BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kyte JA, Røssevold A, Falk RS, Naume B. ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer. J Transl Med 2020;18:252. [PMID: 32576225 DOI: 10.1186/s12967-020-02424-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Wesolowski J, Tankiewicz-kwedlo A, Pawlak D. Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer. Cancers 2022;14:3860. [DOI: 10.3390/cancers14163860] [Reference Citation Analysis]
2 Qian X, Hu W, Yan J. Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option? Front Immunol 2022;13:963533. [DOI: 10.3389/fimmu.2022.963533] [Reference Citation Analysis]
3 Zhao Q, He X, Qin X, Liu Y, Jiang H, Wang J, Wu S, Zhou R, Yu C, Liu S, Zhang H, Tian M. Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer. Front Immunol 2022;13:938439. [DOI: 10.3389/fimmu.2022.938439] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Haist M, Mailänder V, Bros M. Nanodrugs Targeting T Cells in Tumor Therapy. Front Immunol 2022;13:912594. [PMID: 35693776 DOI: 10.3389/fimmu.2022.912594] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Nel AE, Mei KC, Liao YP, Liu X. Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs. ACS Nano 2022. [PMID: 35348320 DOI: 10.1021/acsnano.2c01252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zhang J, Pan S, Jian C, Hao L, Dong J, Sun Q, Jin H, Han X. Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice. Front Immunol 2021;12:819405. [PMID: 35069604 DOI: 10.3389/fimmu.2021.819405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Sakach E, O'Regan R, Meisel J, Li X. Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies. Clin Breast Cancer 2021:S1526-8209(21)00261-5. [PMID: 34629314 DOI: 10.1016/j.clbc.2021.09.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Vivarelli S, Falzone L, Leonardi GC, Salmeri M, Libra M. Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). Int J Oncol 2021;59:75. [PMID: 34396439 DOI: 10.3892/ijo.2021.5255] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
9 Criscitiello C, Corti C, Pravettoni G, Curigliano G. Managing side effects of immune checkpoint inhibitors in breast cancer. Crit Rev Oncol Hematol 2021;162:103354. [PMID: 34029683 DOI: 10.1016/j.critrevonc.2021.103354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gondhowiardjo SA, Handoko, Jayalie VF, Apriantoni R, Barata AR, Senoaji F, Utami IJW, Maubere F, Nuryadi E, Giselvania A. Tackling Resistance to Cancer Immunotherapy: What Do We Know? Molecules 2020;25:E4096. [PMID: 32911646 DOI: 10.3390/molecules25184096] [Cited by in F6Publishing: 2] [Reference Citation Analysis]